Pine Tar Oil Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dark, viscous, terpenoid-phenolic distillate obtained from controlled destructive distillation of Pinus spp. wood. The material is controlled by the manufacturer’s grade code and batch certificate of analysis rather than a global model number; pharmacopoeial identity is confirmed through the relevant regional monograph for pine tar or pine tar oil where available. Because CAS 8011-48-1 is commonly applied to parent pine tar and CAS 8002-09-3 may be used for steam-distilled pine oil, the receiving site must confirm the exact CAS registration and boiling range with the API manufacturer. The veterinary API grade is distinguished by retention of the mid-boiling guaiacol-cresol-resin acid fraction and exclusion of the heavier polycyclic aromatic hydrocarbon tail through a defined distillation endpoint. It is a low-polar liquid at 20–25°C; storage below 15°C may produce reversible sediment that redissolves on warming to 25–30°C.

Receipt and storage are controlled by the site quarantine procedure. Containers are kept sealed under nitrogen where possible because the terpenoid fraction reacts with atmospheric oxygen; oxidation raises peroxide value and shifts the odour profile. The supplier’s certificate of analysis reports peroxide value for the specific lot, and the receiving unit should reject lots exceeding the alert level defined by the finished dosage form stability program. Moisture ingress above 0.5% w/w is not acceptable for non-aqueous capsule and injection intermediates. Microbial quality is evaluated according to Ph. Eur. 2.6.12 and 2.6.13; a non-sterile API for oral solid dosage forms typically requires total aerobic microbial count ≤ 1000 CFU/g and total combined yeasts and moulds ≤ 100 CFU/g. For injectable use, sterility and pyrogen control are applied to the finished solution rather than to the raw oil.

What release criteria separate the veterinary API grade from unstandardised pine tar oil?

The receiving specification is not harmonised across all regional compendia. Release testing therefore uses the supplier’s validated methods mapped to pharmacopoeial general chapters; the list in Table 1 is representative of a full documentary standard. Where a numeric limit is absent from a specific monograph, the alert limit is derived from process capability and finished-product stability data. Published data for this specific configuration is limited, so feed-grade or technical-grade specifications must not be considered interchangeable with the API grade.

Because the terpenoid-phenolic fraction is a low-polar liquid at ambient temperature, solid dosage forms require adsorption or wet granulation before compression. Direct compression without a sorbing carrier is not recommended; the resin fraction can migrate to granule surfaces and cause picking on rotary tablet tooling when powder temperatures exceed 25°C. The processing window for high-shear granulation is narrow: granule surface temperature is maintained between 20°C and 25°C, a ±5°C control band, because the resin acid fraction softens above 30°C and increases punch residue.

For tablet manufacture, the API is pre-sorbed onto silicon dioxide or magnesium aluminometasilicate at 0.5–1.5 g carrier per gram of oil. The sorbate is dry-blended for 5–10 min in a low-shear blender at 20–25°C and relative humidity below 40%. Wet granulation uses an ethanolic binder solution rather than water alone; water increases interfacial tension with the oil phase and produces uneven granule growth. Compression on a rotary tablet press with 10-station tooling is carried out at 15–30 kN. Compression force above 30 kN can express oil to the tablet surface and increase disintegration time. Tablets containing the API typically include croscarmellose sodium at 2–5% w/w; disintegration is measured by Ph. Eur. 2.9.1 and maintained below 30 min for uncoated tablets. Tensile strength is monitored with a hardness tester to stay within 1.5–2.5 MPa; lower values lead to edge chipping during coating.

For capsule filling, neat oil can be filled into hard gelatin capsules only when band sealing is applied. The oil migrates into the capsule shell over storage at 25°C/60% RH, reducing shell brittleness and eventually causing leakage at the cap-body junction. Dilution with medium-chain triglycerides or fractionated coconut oil at 30–50% w/w reduces shell incompatibility and permits standard liquid-fill equipment. Hopper temperature is held at 20–25°C; fill weight variation is controlled to a relative standard deviation of ≤ 2% for 1,000-capsule pilot campaigns. Moisture-scavenging desiccant is required in primary packaging because water migration from shell to core alters the fill viscosity and can delay release.

For powders, granules, and premix, the oil is incorporated by geometric dilution. The initial 1:1 blend with precipitated silica or calcium carbonate is passed through a 0.5 mm sieve, then subsequent dilutions bring the carrier blend to the target assay. Homogeneity is verified by sampling 10 points and assaying guaiacol by GC-FID; a coefficient of variation ≤ 5% is a typical acceptance criterion. Premixes for medicated feed are stored in closed stainless-steel or high-density polyethylene containers; the oil can permeate low-density polyethylene over 30 days at 40°C and reduce potency uniformity.

Granules for sachet filling are dried at 35–40°C in a fluid-bed dryer. Inlet air temperature above 45°C volatilises the low-boiling terpene fraction and can reduce total phenolic assay; loss on drying is monitored by Ph. Eur. 2.2.32 until the target moisture is reached. Dried granules are sieved through 1.0 mm and 0.25 mm screens to remove oversize and fines before filling.

Coated tablets require an isolation layer when aqueous film coating is applied. The hydrophobic API surface reduces adhesion of hydroxypropyl methylcellulose-based coatings; a seal coat of hydroxypropyl methylcellulose or polyvinyl alcohol-based system at 1–2% weight gain restores coating uniformity. Pan speed is limited to 4–10 rpm in a 24-inch coating pan to prevent tablet attrition from the plasticised oil surface.

Comparative contaminant control across pine-derived product families

Differentiation from related pine products is driven by distillation endpoint, total phenolic retention, and controlled residual wood-derived impurities. The veterinary API grade is not equivalent to parent pine tar, technical pine oil, or rectified pine tar oil. Parent pine tar contains a larger resin and particulate fraction and requires filtration before liquid-dosage use; technical pine oil is terpene-rich and lower in guaiacol and cresol markers; rectified pine tar oil removes heavy resin acids but may also strip the phenolic actives if over-rectified. Coal tar-derived products are outside this product family and are distinguished by a different polycyclic aromatic hydrocarbon profile and CAS identity.

In injection-compounding suites, water removal is the first critical limit. Pine tar oil intended for injectable formulations must meet the low-water specification; otherwise, aqueous co-solvent systems may fail clarity at 0–5°C storage. The oil is not water-soluble. Aqueous injectable formulations are prepared with propylene glycol, polyethylene glycol 300, and polysorbate 80, with solvent ratios fixed by phase-solubility studies and filtered through 0.22 µm PVDF. Terminal moist-heat sterilisation at 121°C for 15 min is feasible only when the formulation remains monophasic above autoclave temperature; otherwise, aseptic filtration is required. Particulate matter is controlled by USP <788> for small-volume injections; visible-particulate counts above the pharmacopoeial threshold require re-filtration. Bacterial endotoxin limits are calculated from the labelled dose; a typical veterinary parenteral limit is ≤ 5 EU/kg body weight, but the registered product monograph is definitive.

Oral solutions are prepared with emulsifying agents or alkali-solubilised phenolic fractions. If the pH is raised above 8.0, the phenolic fraction oxidises more rapidly and can form dark polymeric residues on container surfaces; the target pH range for aqueous oral solutions is therefore 5.5–8.0. Buffering is confirmed by stability data under 25°C/60% RH and 40°C/75% RH conditions.

Operational boundaries include avoidance of strong oxidizers, including peroxide-based sanitizers, because terpenoid components undergo exothermic oxidation. The API should not be pre-mixed with amine-based additives in high-shear equipment; phenolic constituents can form coloured reaction products that interfere with content uniformity testing. At relative humidity above 60%, coated tablets containing the API require a desiccant in primary packaging. Where continuous twin-screw granulation is used, the barrel segments are cooled to 20–25°C to prevent resin softening; barrel temperature excursions above 30°C have been associated with increased torque and binder blockage at the feed zone. Batch-to-batch variation in acid value, typically managed within the 40 mg KOH/g ceiling, may require a 1–2% adjustment in binder solution mass during wet granulation when wood source lot changes alter the resin acid load.